Cancer vaccines: novel approaches and new promise - PubMed (original) (raw)

Review

Cancer vaccines: novel approaches and new promise

B R Minev et al. Pharmacol Ther. 1999 Feb.

Abstract

Cancer vaccines are a promising tool in the hands of the clinical oncologist. We have summarized the most recent findings and achievements in this exciting field. Tumor-associated antigens, as a basis for the new cancer vaccines, are reviewed. We emphasize novel approaches for the design of safe and more effective vaccines for cancer. We also discuss the possible clinical applications and the future prospects for vaccine development.

PubMed Disclaimer

Similar articles

• Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
  Minev BR, Guo F, Gueorguieva I, Kaiser HE. Minev BR, et al. In Vivo. 2002 Nov-Dec;16(6):405-15. In Vivo. 2002. PMID: 12494883 Review.
• Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
  Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Bodey B, et al. Anticancer Res. 2000 Jul-Aug;20(4):2665-76. Anticancer Res. 2000. PMID: 10953341 Review.
• Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
  van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. van der Burg SH, et al. Adv Drug Deliv Rev. 2006 Oct 1;58(8):916-30. doi: 10.1016/j.addr.2005.11.003. Epub 2006 Aug 12. Adv Drug Deliv Rev. 2006. PMID: 16979788 Review.
• New cancer vaccine approaches.
  Kaplan JM. Kaplan JM. Drugs Today (Barc). 2004 Nov;40(11):913-29. doi: 10.1358/dot.2004.40.11.872580. Drugs Today (Barc). 2004. PMID: 15645004 Review.
• Developing recombinant and synthetic vaccines for the treatment of melanoma.
  Restifo NP, Rosenberg SA. Restifo NP, et al. Curr Opin Oncol. 1999 Jan;11(1):50-7. doi: 10.1097/00001622-199901000-00012. Curr Opin Oncol. 1999. PMID: 9914879 Free PMC article. Review.

Cited by

• Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma.
  Hassanin H, Serba S, Schmidt J, Märten A. Hassanin H, et al. Clin Exp Immunol. 2009 Oct;158(1):125-32. doi: 10.1111/j.1365-2249.2009.03935.x. Clin Exp Immunol. 2009. PMID: 19737239 Free PMC article.
• Translating tumor antigens into cancer vaccines.
  Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Buonaguro L, et al. Clin Vaccine Immunol. 2011 Jan;18(1):23-34. doi: 10.1128/CVI.00286-10. Epub 2010 Nov 3. Clin Vaccine Immunol. 2011. PMID: 21048000 Free PMC article. Review.
• Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
  Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Leitner WW, et al. Cancer Res. 2000 Jan 1;60(1):51-5. Cancer Res. 2000. PMID: 10646851 Free PMC article.
• Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy.
  Mohite P, Yadav V, Pandhare R, Maitra S, Saleh FM, Saleem RM, Al-Malky HS, Kumarasamy V, Subramaniyan V, Abdel-Daim MM, Uti DE. Mohite P, et al. ACS Omega. 2024 Feb 5;9(7):7277-7295. doi: 10.1021/acsomega.3c06501. eCollection 2024 Feb 20. ACS Omega. 2024. PMID: 38405458 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database